Hepatocellular Carcinoma (HCC) in HCV: Screening and Surveillance | June 17, 2026
Date of Presentation: June 17, 2026
Type: Past Presentation
Audience: Clinical
Program: Hepatitis C
Keywords: #hcc #hcv #prevention #surveillance
In this presentation, Dr. Paulina Deming, PharmD, PhC, reviews the surveillance recommendations for HCC, the current incidence of HCC, best practices for prevention of HCC, how to interpret liver imaging reports, and considerations for the use of Alpha Fetal Protein (AFP).
Presented by:
Dr. Paulina Deming
Dr. Paulina Deming is an Associate Professor-Clinical Educator within the Pharmacy Practice and Administrative Sciences Department at the College of Pharmacy at the University of New Mexico Health Sciences Center (UNMHSC). Dr. Deming completed a general practice residency and infectious diseases pharmacotherapy residency at UNMHSC. Her interests are focused in hepatitis C virus (HCV) infections and clinical therapeutics. She is the assistant director for the Project ECHO (Extension for Community Healthcare Outcomes) HCV clinic and serves on Project ECHO’s expert faculty panel advising providers on HCV care in community, corrections, and within the Indian Health Services settings. Licensed as a pharmacist clinician, she sees patients through the UNMHSC’s HCV clinic and the Truman HCV-HIV coinfection clinic. In addition to teaching and clinical work, Dr. Deming has co-authored papers on the management of HCV infections as well as HCV treatment outcomes in real-world settings.
Read the full bio …Resources Provided:
- Activity Evaluation and Claiming CE
- Tribal Disease Intervention Training – July 2026
- Ending the Syndemic Training – June 2026
Date added: May 6, 2026



















































































